IVIG Dosing for Multiple Sclerosis Relapse
For an acute MS relapse, administer IVIG at 0.4 g/kg/day for 5 consecutive days (total dose 2 g/kg), which can be repeated monthly if needed for refractory cases. 1
Evidence-Based Dosing Protocol
The standard regimen for MS relapse treatment consists of:
- Loading dose: 0.4 g/kg body weight daily for 5 consecutive days 1, 2
- Total cumulative dose: 2 g/kg over the 5-day period 3
- Maintenance dosing (if needed): 0.4 g/kg every 4-6 weeks for prevention of future relapses 2, 4
This dosing mirrors the established protocol used in other immune-mediated neurological conditions like Guillain-Barré syndrome and is consistent with American Academy of Neurology recommendations for immunomodulatory therapy 5, 3.
Clinical Context and Timing
IVIG should be initiated within the first 5 days after starting corticosteroids if used as add-on therapy, or can be used as monotherapy when corticosteroids are contraindicated 3, 1. The research demonstrates that IVIG monotherapy (0.4 g/kg/day for 5 days) produces comparable clinical and radiological outcomes to high-dose intravenous methylprednisolone in treating acute MS relapses 1.
Alternative Dosing Considerations
Some protocols have used different regimens:
- 1 g/kg daily for 2 days (total 2 g/kg) repeated every 4 weeks showed efficacy in preventing exacerbations in relapsing-remitting MS 4
- Monthly maintenance: 0.4 g/kg every 6 weeks after initial loading demonstrated long-term safety over 10 years of treatment 2
However, the 5-day loading protocol (0.4 g/kg/day) remains the most extensively studied and recommended approach for acute relapses 1.
Safety Profile
IVIG demonstrates excellent tolerability in MS patients:
- Headache is the most common adverse event during loading (12.6% of patients) 2
- Annual adverse event rate during maintenance is only 4.4% in the first year, decreasing with continued treatment 2
- No severe adverse events, thromboembolic complications, or acute renal failure were recorded in a cohort of 293 patients receiving 9,281 infusions over 10 years 2
Important Caveats
Check serum IgA levels before administration, as IgA deficiency can lead to severe anaphylaxis; use IgA-depleted preparations if deficiency is detected 6.
Do not administer plasmapheresis immediately after IVIG, as it will eliminate the therapeutic effect 3. If both treatments are needed, plasmapheresis should be given first, followed by IVIG.
The evidence supporting IVIG for MS relapses comes primarily from smaller studies compared to interferon-beta trials, but meta-analysis confirms significant reduction in relapse rates (effect size -0.5, P=0.00003) and improvement in disability scores 7, 8.